UNSPSC 51144901: Fenbutrazate

This classification denotes an anorexiant with the molecular formula C23H29NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) BKY8H56395, chemically known as butyric acid, 2-phenyl-, 2-(3-methyl-2-phenylmorpholino)ethyl ester but more generally known as fenbutrazate, which bears US NIH Compound Identifier 20395. European Medicines Agency schedules Fenbutrazate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07544MIG.

UNSPSC 51144901 Fenbutrazate, a Commodity code, shows minimal alignment between its nominal scope and recent state and local procurement activity. The three recent opportunities tagged to this code involve naloxone kits, therapeutic pharmacy programs, and generic multi-source pharmaceuticals and over-the-counter products — none of which are fenbutrazate, an agricultural fungicide with no evident use in state and local government procurement. The mismatch suggests either tagging errors in the source data or dormant procurement activity under this code's actual commodity scope.

The issuing bodies across the three opportunities span state health agencies, counties, and cooperative purchasing alliances: Seminole County, Florida (health procurement); Texas Health and Human Services Commission (pharmacy benefit program); and the Minnesota Multistate Cooperative Purchasing Alliance (cooperative vehicle serving multiple state and local jurisdictions, including Oregon). The Seminole County IFB (due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to a county health building. The Texas HHS Commission issued an exploratory RFI (April 3, 2026) on direct-to-manufacturer prescription programs to inform future procurement strategy. The Minnesota MMCAP RFP (due March 26, 2026) solicited generic pharmaceuticals and OTC products across multiple state and local facilities, with awards effective July 1, 2026, and pricing weighted 75 percent on competitiveness. No recent opportunities directly match fenbutrazate procurement, and the code shows little relevant state and local activity grounded in its actual commodity definition.